A study to determine the safety and anti-viral activity of ARB-1740 in patients with chronic hepatitis B virus (HBV) infection.
Phase 1
Terminated
- Conditions
- Chronic hepatitis B virus infection
- Registration Number
- ACTRN12617000557336
- Lead Sponsor
- Arbutus Biopharma Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ARB-1740 target to achieve anti-HBV activity in phase 1 trials?
How does ARB-1740's antiviral efficacy compare to nucleos(t)ide analogs in chronic HBV patients?
Which biomarkers correlate with ARB-1740 response in non-cirrhotic chronic hepatitis B subjects?
What adverse event profiles are reported for RNAi therapeutics like ARB-1740 in HBV trials?
How does ARB-1740's pharmacokinetics compare to other nucleic acid-based HBV treatments in phase 1 studies?